In the study by Wu et al. (2018), both bufalin and BF211 (a derivative of bufalin) were shown to suppress the progression of MM by inhibiting the IL-6/JAK2/STAT3 pathway in vivo and in vitro. Here, STAT3 is linked to Miyoshi myopathy.